Global GPCR Agonist Market Size, Trends and Growth Opportunity, By Product Type (Instruments, Reagents and Chemicals, and Kits), By Technology (High-Throughput Functional Cell Based Assay, Fluorescence Microscopy Analysis, Triple-Quadrupole Mass Spectrosc

Global GPCR Agonist Market Size, Trends and Growth Opportunity, By Product Type(Instruments, Reagents and Chemicals, and Kits), By Technology (High-Throughput Functional Cell Based Assay, Fluorescence Microscopy Analysis, Triple-Quadrupole Mass Spectroscopy, Luciferaase Assay, Real-Time Bioluminescence, Resource Energy Transfer (Bret) Assay, Reporter Gene Assay, Camp Assay, Cgmp Assay, and High Thtroughput Screening (HTS) Assay), By Application(Cancer Research, Cardiovascular System Diseases, Central Nervous System Diseases, Drug Discovery, and Others), By End-Use Industry (Academic Institutes and Research Institutes, Clinical Research Organizations, and Biophrmaceutical Companies), By Region and Forecast Till 2027.

Global GPCR Agonist Market

Global GPCR Agonist Market was valued at USD 2.5 billion in 2021, which is expected to reach USD 11.7 billion by 2027, with 20.91% CAGR from 2022 to 2027.

GPCR antagonists, also known as protein-coupled receptors, play a significant role in pathways that are relevant to medicine. These are used to treat a variety of illnesses, including circulatory system ailments, autoimmune diseases, and diseases of the central nervous system (CNS). Additionally, GPCR agonists are utilized to treat CNS conditions like Alzheimer's, Parkinson's, and Huntington's disease, which are prevalent in the elderly population.

Market Drivers

The global GPCR agonist market is anticipated to develop as the prevalence of various disorders such as cancer, autoimmune diseases, and Central Nervous System Diseases (CNS) rises. Additionally, an improvement in the efficiency of identifying pharmaceutically relevant drug candidates is anticipated to fuel the expansion of the worldwide GPCR agonist market. Additionally, throughout this projection period, research and development in drug discovery is anticipated to drive the growth of the worldwide GPCR agonist market. Additionally, an increase in allosteric modules, biased diagnostics, and the use of biological therapies will spur demand for GPCR agonists globally.

Market Restraints

Low abundance, poor stability, and structural plasticity leading to various conformations are some of the characteristics that make it difficult to purify GPCRs. Despite this, a number of non-rhodopsin GPCR structures have been determined from purified proteins utilizing a generally comparable approach of one or more affinity stages. These elements could impede market expansion.

Market Segmentation

Global GPCR Agonist market is segmented into product type, technology, application and end user. By product type it is segmented into instruments (microfluidicdroplet generator, single-inlet microfluidic device, air compressor, micromanipulator, confocal microscope, mitos-p-pump, and microplate fluorometer), reagents and chemicals (cell line, repoter gene, and media), and kits. By technology it is segmented into high-throughput functional cell based assay, fluorescence microscopy analysis, triple-quadrupole mass spectroscopy, luciferaase assay, real-time bioluminescence, resource energy transfer (bret) assay, reporter gene assay, camp assay, cgmp assay, and high thtroughput screening (hts) assay. By application it is segmented into cancer research, cardiovascular system diseases, central nervous system diseases, drug discovery, and others. By end user it is segmented into academic institutes and research institutes, clinical research organizations, and biophrmaceutical companies.

Regional Analysis

The GPCR Agonist market segmented into five regions North America, Europe, Latin America, Asia Pacific, Middle East and Africa. The Asia-Pacific region is anticipated to expand significantly over the course of the forecast period due to the region's unfulfilled market needs, rising per capita income, and the economic development of nations like China and India, as well as rising government investment in the biotechnology and biopharmaceutical sector.

Market Key Players

Various key players are discussed in this report such as European Collection of Cell Culture, Clontech Laboratries, Inc.,Nacalai Tesque, GE Healthcare, Thermo Fisher Scientific, Nano-Glo™ Luciferase Assay System, Promega, Fluoroskan Ascent, Sigma-Aldrich, Wako Pure Chemical Industries, Zymo Research, Clontech Laboratries, Inc.,and Drummond Scientific Co.

Market Taxonomy

By Product Type

• Instruments
• Microfluidic droplet generator
• Single-inlet microfluidic device
• Air compressor
• Micromanipulator
• Confocal microscope
• Mitos P-Pump
• Microplate Fluorometer
• Reagents and chemicals
• Cell line
• Repoter gene
• Media
• Kits

By Technology

• High-Throughput Functional Cell-Based Assay
• Fluorescence Microscopy Analysis
• Triple-quadrupole mass spectrometry
• Luciferase Assay
• Real-Time Bioluminescence Resonance Energy Transfer (BRET) Assay
• Reporter gene assay
• cAMP assay
• cGMP assay
• High Throughput Screening (HTS) Assay

By Application

• Cancer research
• Cardiovascular System diseases
• Central Nervous System (CNS) diseases
• Immune System diseases
• Other Therapeutic Areas
• Drug discovery

By End User

• Academic Institutes And Research Institutes
• Clinical Research Organizations
• Biopharmaceutical Companies

By Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Key Question Addressed by the Report

• What are the Key Opportunities in Global GPCR Agonist Market?
• What will be the growth rate from 2022 to 2027?
• Which segment/region will have highest growth?
• What are the factors that will impact/drive the Market?
• What is the role of key players in the value chain?